NextBioMedical Co

NextBioMedical Co FCF per Share

The Free Cash Flow per Share of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is -233.98 KRW. In the previous year, Free Cash Flow per Share was -202.80 KRW — a change of 15.38% (lower).

FCF per Share

-233.98KRW

YoY

15.38%

Last updated:

Free Cash Flow per Share of NextBioMedical Co is 2025 -233.98 KRW. Free Cash Flow per Share of NextBioMedical Co was 2024 -202.80 KRW. It decreases by 15.38% lower compared to the previous year.

The NextBioMedical Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2021
-770.53 KRW
Jan 1, 2022
-1,049.35 KRW
Jan 1, 2023
-527.53 KRW
Jan 1, 2024
-202.80 KRW
Jan 1, 2025
-233.98 KRW
The NextBioMedical Co FCF per Share history
YEARFCF per ShareYoY
-233.98KRW+15.38%
-202.80KRW-61.56%
-527.53KRW-49.73%
-1,049.35KRW+36.18%
-770.53KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Free Cash Flow per Share of NextBioMedical Co is -233.98 KRW in 2025.

Free Cash Flow per Share of NextBioMedical Co changed from -202.80 KRW to -233.98 KRW, representing a 15.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NextBioMedical Co

All Key Metrics — NextBioMedical Co